Meyer Handelman Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Meyer Handelman Company’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$257K	Hold	575	–	–	0.01%	201
2025 Q4	$261K	Buy	+575	New	+$248K	0.01%	201
2024 Q4	–	Sell	-575	Closed	-$267K	–	218
2024 Q3	$267K	Hold	575	–	–	0.01%	192
2024 Q2	$270K	Hold	575	–	–	0.01%	190
2024 Q1	$240K	Hold	575	–	–	0.01%	192
2023 Q4	$234K	Buy	+575	New	+$212K	0.01%	182
2023 Q3	–	Sell	-575	Closed	-$202K	–	197
2023 Q2	$202K	Buy	+575	New	+$194K	0.01%	182

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Meyer Handelman Company's VRTX Position: Q1 2026 in Review

Meyer Handelman Company held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 575 shares worth $257K. The position accounts for 0.01% of the portfolio, ranked #201.

Meyer Handelman Company first reported a position in VRTX in Q2 2023 and has held it in 7 quarters since. The position peaked at $270K in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Meyer Handelman Company held 575 shares of Vertex Pharmaceuticals worth $257K as of Q1 2026.
Meyer Handelman Company left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up 0.01% of Meyer Handelman Company's portfolio in Q1 2026, its #201 holding.
Meyer Handelman Company first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 7 quarters since.
Meyer Handelman Company's Vertex Pharmaceuticals position peaked at $270K in Q2 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Meyer Handelman Company's 13F filing for Q1 2026, filed 20 Apr 2026.